Dylai amnewid cynhyrchion HRT fod yn benderfyniad ar y cyd rhwng menyw a chlinigydd sydd â phrofiad o roi HRT ar bresgripsiwn. O dan rai amgylchiadau, mae’n bosibl y bydd yn briodol i fferyllydd cymunedol weinyddu cynnyrch HRT amgen pan fo’r cynnyrch hwnnw’n glinigol gyfatebol. Cyhoeddwyd pedwar Protocol Prinder Difrifol pellach ar 23 Mai sy’n caniatáu i fferyllwyr cymunedol gyflenwi mathau amgen penodol o HRT ar gyfer presgripsiynau o Oestrogel, Ovestin, Sandrena a Lenzetto, pan fo cwnsela priodol yn digwydd a dim ond gyda chydsyniad menyw.
Switching between HRT products should be a shared decision between a woman and a clinician with experience in prescribing HRT. In limited circumstances, it may be appropriate for a community pharmacist to dispense an alternative HRT product where it is clinically equivalent. Four further SSPs were published on 23 May allowing community pharmacists to supply specified alternative forms of HRT against prescriptions for Oestrogel, Ovestin, Sandrena and Lenzetto where appropriate counselling takes place and only with a woman’s consent.